EyeNet Magazine
CHECK OUT THE EYENET BLOG!

Looking at the May issue through an international lens: 
0511-cov

10 Approaches That May Push Back AMD

Numerous drugs for the treatment of wet AMD are currently under study. From anti-VEGF drugs to radiation and integrin agonists to gene therapy. EyeNet looks at 10 of the most talked-about strategies. (more)

The slideshow below presents Ophthotech's E10030 and ARC1905, and each therapy's method of action. The E10030 takes a vascular stabilization approach to preventing progression of wet AMD, while the ARC1905 uses complement inhibition.

(Slides provided courtesy of Ophthotech.)
 
 
 
 
 
0511_Blink
Blink

Mystery Image: What do you see?
 
 
Morning Rounds

The Red Eye From Rio

The young immigrant had been working long hours in a pizzeria when he began suffering pain, redness and decreasing vision in his right eye. What's your diagnosis? (more)		 AMR_05
 
 
Opinion

Medical Loss Ratios: Another Chance to Game the System? 

Certain commonly used words and phrases offend me. Like “provider,” for example. Another term that rankles me is “medical loss ratio,” abbreviated MLR, which refers to the percent of premium a health insurer actually has to pay on behalf of insureds when they obtain health care.

It takes some detail to explain what’s distasteful about MLR. By contrast, it doesn’t take any explaining to see what’s wrong with “provider.” It’s because the system’s already been fully gamed on that one. (more)		 Mills376
 
 
WRITE TO US

We welcome letters on all issues raised in EyeNet, and on ophthalmology generally.

Share your thoughts with your colleagues by sending a letter to eyenet@aao.org.
 












About Us Academy Jobs Privacy Policy Contact Us Terms of Service Medical Disclaimer Site Index

© American Academy of Ophthalmology 2012